2 AGENDA Multiple Sclerosis (MS) Impact of MS on the individual Current Treatments & Unmet Need MS is the Most Common Non-traumatic Cause of Neurological Disability in Young Adults MS is a chronic autoimmune inflammatory disease of the central nervous system (CNS) associated with progression of disability Causes of MS are unknown but are thought to involve a combination of genetic, environmental and autoimmune factors MS has an unpredictable and potentially devastating impact on those affected MS affects people in the prime of life, with a typical age of onset between 20 and 40 Canada has one of the highest prevalence of MS in the world, measured at 240 per 100,000 1 An estimated 55,000 75,000 Canadians have MS 2 3 new MS cases diagnosed every day (1,000 new cases/yr) 2 1. Beck CA et al. Mult Scler MS Society of Canada:

3 The Most Common Form of MS Is Relapsing Remitting Form (RRMS-85%) Demyelination, inflammation, neuronal damage Remyelination, resolution of inflammation, neuronal repair (complete or incomplete) RRMS Disease Severity Relapse Several days to several weeks in duration Remission Disability Time Time Hauser SL, Goodin DS. Harrison s Principles of Internal Medicine. 17th ed. New York, NY: McGraw-Hill; 2008: The Extent of Disability Ultimately Depends on the Balance Between Damage and Repair in the CNS Inflammatory attacks (relapse) Lymphocytes invade CNS and damage/destroy nerve cells Stimulates Balance of damage & repair determines accumulation of damage leading to progression Nerve damage Progressive disability Myelination Normal physiological process for nerve cell repair Protects Time is variable for progressive disability to become apparent Compston A et al. Lancet 2002;359(9313):

Conflict of Interest Declaration Overview of New Medications for Multiple Sclerosis I or my spouse have no actual or potential conflict of interest in relation to this activity. Crystal Obering, Pharm.D.,

Multiple Sclerosis: What You Need To Know For Professionals What will I learn today? The Basics: What is MS? Living with MS: A Family Affair We Can Help: The National MS Society What MS Is: MS is thought

What is Multiple Sclerosis? Gener al information Kim, diagnosed in 1986 What is MS? Multiple sclerosis (or MS) is a chronic, often disabling disease that attacks the central nervous system (brain and spinal

AVONEX/BETASERON/COPAXONE/EXTAVIA/GILENYA/REBIF/TYSABRI Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 5 PATIENT INFMATION Surname First Name Middle Initial Sex Date

Treatment guidelines for relapsing MS and the two step approach for disease modifying therapy Klaus Schmierer, PhD FRCP Blizard Institute, Barts and The London School of Medicine & Dentistry Barts Health

Patient Group Input to CADTH Section 1 General Information Name of the drug CADTH is reviewing and indication(s) of interest Name of patient group/author of submission Patient group s contact information:

Which injectable medication should I take for relapsing-remitting multiple sclerosis? A decision aid to discuss options with your doctor This decision aid is for you if you: Have multiple sclerosis Have

Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks

Progress in the field: therapeutic improvements for all patients? Krzysztof Selmaj, Department of Neurology, Medical University of Lodz, PL Warsaw 15 May, 2015 Main features of MS Inflammation Demyelination

Choices Disease Modifying Treatments Disease modifying treatments (DMTs) are medications which modify the disease course. They target inflammation and are designed to reduce the damage caused by relapses.

Putting the Cart Back Behind the Horse: Converting a population based research database into an electronic clinical patient record The Story Crash course on Multiple Sclerosis A little bit of History of

Disease Modifying Therapies for MS The term disease-modifying therapy means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks

Study Support Materials Cover Sheet Document Title ESCALATE Patient Brochure Intended Audience This brochure is designed to be given to potentially eligible patients as a take-home summary of key information

Brochure More information from http://www.researchandmarkets.com/reports/1408035/ Multiple Sclerosis Drug Discoveries - What the Future Holds Description: The recent approval in the US of Novartis' orally

1 It is the National MS Society s mission to mobilize people and resources to drive research for a cure and to address the challenges of everyone affected by MS. The National MS Society, Greater Northwest

ABN Guidelines for 2007 Treatment of Multiple Sclerosis with ß-interferon and Glatiramer Acetate Published by the Association of British Neurologists Ormond House, 27 Boswell Street, London WC1N 3JZ Contents

Revised (2009) guidelines for prescribing in multiple sclerosis INTRODUCTION In January 2001, the (ABN) first published guidelines for the use of licensed disease modifying treatments (ß-interferon and

DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS* Benjamin M. Greenberg, MD, MHS ABSTRACT Four major disease-modifying therapies are discussed within the context of relapsing and remitting

How to S.E.A.R.C.H. SM for the Right MS Therapy For You! The Changing Landscape The first treatment for relapsing-remitting multiple sclerosis (RRMS) was approved by the United States Food and Drug Administration

CNS DEMYLINATING DISORDERS Multiple sclerosis A Dutch saint named Lidwina, who died in 1433, may have been one of the first known MS patients. After she fell while ice skating, she developed symptoms such

Treatments for MS: Immunotherapy There are currently several disease-modifying therapies approved for people with MS in Australia. These therapies, called immunotherapies, work to reduce disease activity

New Developments in the Treatment and Management of Multiple Sclerosis Myla D. Goldman, MD, MS For a CME/CEU version of this article, please go to www.namcp.org/cmeonline.htm, and then click the activity

FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to

TITLE: Treatment of Patients with Multiple Sclerosis: A Review of Guidelines DATE: 13 March 2013 CONTEXT AND POLICY ISSUES Multiple sclerosis (MS) is an unpredictable, often disabling disease of the central

MS: The Treatment Paradigm, Pathway to Success for Improved Patient Outcomes Jack Burks, MD For a CME/CEU version of this article please go to www.namcp.org/cmeonline.htm, and then click the activity title.

5 th MS Research Day, June 14 th 2014 New treatments in MS What s here and what s nearly here David Miller Queen Square MS Centre at UCL and UCLH Course of MS and its treatment Relapsing remitting Disability

What is MS? 1 Neuron Damaged myelin due to inflammation MS is a chronic immunemediated disease that affects the central nervous system (CNS) Is a disease that affects both white and gray matter Interrupted

New perception of disability including cognition, fatigue, pain and other impairments related to MS Diego Cadavid, MD Director, MS Clinical Development Biogen Idec 1 Need for clarity on terminology for

Information About Medicines for Multiple Sclerosis Information About Medicines for Multiple Sclerosis What is multiple sclerosis? 1 Multiple sclerosis (MS) is a lifelong disease that affects your brain

Information about medicines for multiple sclerosis Information about medicines for multiple sclerosis What is multiple sclerosis? 1 Multiple sclerosis (MS) is a lifelong disease that affects your brain

MS Society response to the NICE Appraisal Consultation Document (ACD) on Fingolimod About the MS Society Established in 1953 and with over 38,000 members and 290 branches, the MS Society is the UK s largest

Multiple Sclerosis & MS Ireland Media Fact Sheet This fact sheets gives a summary of the main facts and issues relating to Multiple Sclerosis and gives an overview of the services offered by MS Ireland.

What is Multiple Sclerosis? Multiple Sclerosis (MS) is a disease of the central nervous system (including the brain and spinal cord) in which the nerves degenerate. A disease of the central nervous system

Can an administrative drug claims database be used to understand claimant drug utilization? By Elaine McKenzie, BSP, MBA, Consultant, TELUS Health Analytics Elaine McKenzie is a consultant who works with

The importance of early intervention clinician perspective Øivind Grytten Torkildsen «You can never diagnose MS too late» Neuroradiologist from Norway, early 1990s Prognosis in untreated MS Early diagnosis

Disease modifying drug therapy what you need to know Third Edition Karen Alldus Simon Webster SECTION 2 We hope you find the information in this book helpful. If you would like to speak with someone about

0 A Letter From the MS Coalition The treatment of multiple sclerosis (MS) requires a comprehensive management strategy. One important component of that strategy is modifying the disease course. When deciding

Use of Observa,onal Data to Make Causal Inferences About Treatment Decisions in Mul,ple Sclerosis Brian Healy, PhD Disclosures n I receive research support from Merck Serono and Novar,s Outline n Background

Media Release Basel, 28 June 2016 Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA OCREVUS is the first investigational medicine

Resources for the Primary Care Provider Please print these out for reference Resources for providers American Academy of Neurology www.aan.com Provides education and resources, such as guidelines for clinical

Oxford University Hospitals NHS Trust Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis Information for patients page 2 What is Natalizumab and what is it used for? Natalizumab is an